BICO Group
43,16 SEK +1,79%2 investorer følger denne virksomhed
BICO Group is active in medical technology. The company specializes in bio convergence and provides technology, products, and services for biology. With a focus on the application areas bioprinting, multi-omics, cell line development, and diagnostics, the company develops and markets technology that enables researchers to grow cells in 3D environments, conduct drug screening, and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
BICO
Daglig lav / høj pris
41,68 / 43,8
SEK
Markedsværdi
3,05 mia. SEK
Aktieomsætning
4,4 mio. SEK
Volumen
102 t
Seneste videoer
Finanskalender
Delårsrapport
20.08.2024
Delårsrapport
13.11.2024
Årsrapport
19.02.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Erik Gatenholm | 13,6 % | 20,5 % |
Sartorius AG | 10,1 % | 8,5 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
Bulletin from Annual General Meeting in BICO Group AB (publ)
BICO publishes adjusted Annual and Sustainability Report 2023
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
![BICO, Audiocast with teleconference, Q1, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/e0ae8192-bd99-4224-a6cd-569d585ff682.png)
BICO, Audiocast with teleconference, Q1, 2024
Publication of BICO Group Interim report January-March 2024
BICO changes method for impairment test of goodwill resulting in retroactive impairment of goodwill for 2022 and 2023 and provides preliminary figures for Q1 2024
Invitation to the presentation of BICO’s interim report Q1, 2024
Anders Fogelberg appointed as Chief Commercial Officer for BICO Group AB (publ)
Notice to attend the Annual General Meeting in BICO Group AB (publ)
Founders leave after eight years
BICO Publishes Annual and Sustainability Report 2023
![BICO, Audiocast with teleconference, Q4, 2023](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/46a00eef-72f4-439f-b728-929e0070887e.png)
BICO, Audiocast with teleconference, Q4, 2023
Publication of BICO Group Year-end report 2023
BICO announces goodwill impairment of SEK 582m and provides preliminary figures for Q4 2023
Invitation to the presentation of BICO’s interim report Q4, 2023
Catharina Nordlund is appointed Global Head of HR for BICO Group AB (publ)
BICO company Biosero has signed an agreement to develop laboratory automation solutions to a value of 28 MUSD
BICO has completed the divestment of the Berlin property for a total of EUR 21m
![BICO, Audiocast with teleconference, Q3, 2023](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/34f338c7-c628-462a-9e0b-e284586ea778.png)